Late HIV Testing in a Cohort of HIV-Infected Patients in Puerto Rico

Katherine Y. Tossas-Milligan, MS, PhD(c)*; Robert F. Hunter-Mellado, MD, MS†;
Angel M. Mayor, MD, MS†; Diana M. Fernández-Santos, EdD, MS†;
Mark S. Dworkin, MD, MPHTM*

Objective: Late HIV testing (LT), defined as receiving an AIDS diagnosis within a year of one's first positive HIV test, is associated with higher HIV transmission, lower HAART effectiveness, and worse outcomes. Latinos represent 36% of LT in the US, yet research concerning LT among HIV cases in Puerto Rico is scarce.

Methods: Multivariable logistic regression analysis was used to identify factors associated with LT, and a Cochran–Armitage test was used to determine LT trends in an HIV-infected cohort followed at a clinic in Puerto Rico specialized in the management and treatment of HIV.

Results: From 2000 to 2011, 47% of eligible patients were late testers, with lower median CD4 counts (54 vs. 420 cells/mm3) and higher median HIV viral load counts (253,680 vs. 23,700 copies/mL) than non-LT patients. LT prevalence decreased significantly, from 47% in 2000 to 37% in 2011. In a mutually adjusted logistic regression model, males, older age at enrollment and past history of IDU significantly increased LT odds, whereas having a history of amphetamine use decreased LT odds. When the data were stratified by mode of transmission, it became apparent that only the category men who have sex with men (MSM) saw a significant reduction in the proportion of LT, falling from 67% in 2000 to 33% in 2011.

Conclusion: These results suggest a gap in early HIV detection in Puerto Rico, a gap that decreased only among MSM. An evaluation of the manner in which current HIV-testing guidelines are implemented on the island is needed. [*Corrected and Republished Article for: P R Health Sci J 2016;35:113-121*]

Key words: Late HIV diagnosis, Puerto Rico HIV, AIDS diagnosis, Late HIV testing, HIV trends

In 2009, an estimated 32% of persons diagnosed with HIV in the United States (US) were diagnosed with AIDS within 1 year of their initial HIV diagnosis (1), a phenomenon referred to as late testing (LT). LT patients tend to delay initiating HIV treatment and are prone to requiring more complicated treatments, worse overall prognoses (2), the diminished recovery of CD4 T-lymphocytes (3), and higher mortality, even after the receipt of antiretroviral therapy (4). A patient who is unaware that he or she is infected with HIV runs the risk of unknowingly transmitting the virus; in addition, the medical costs associated with that individual's treatment are likely to increase substantially (5).

Although US Latinos represent 20% of all new HIV infections, they account for 36% of late testers (1). The heterogeneity of the "Latino" classification complicates addressing this disparity given that it comprises people from over 20 countries (6), with differing risk factors, behaviors, and rates of infections. For example, 25% of all Puerto Ricans diagnosed with HIV received the infection via past or current injection drug use (IDU), a transmission method that is significantly associated with LT; this compares to the only 6% of Mexicans who acquired the

infection in a like manner (1). Additionally, the prevalence of undiagnosed HIV infections in Puerto Rico (PR), estimated at 36%, is twice that of said prevalence in the US (7). Puerto Ricans are the second largest Hispanic/Latino group in the US (8). There are an estimated 4.9 million Puerto Ricans living on the mainland and 3.7 million living on the island, all of whom are free to migrate to and from the US (8). Therefore, LT among HIV-infected persons on the island may be relevant to the epidemiology of HIV among Puerto Ricans on the mainland.

However, data concerning LT among HIV-infected persons in PR are scarce. A review of the scientific literature identified no publications that examined the epidemiology of LT among HIV-

infected individuals living in PR. Determining the prevalence of and factors associated with LT should inform efforts to decrease this important public health problem by providing data to design programs targeting those identified at greatest risk for LT. The main objective of this study was to determine factors associated with and describe trends of LT in a cohort of HIV-infected individuals who entered HIV care in PR from 2000 through 2011.

Materials and Methods

Data were obtained from baseline questionnaires completed by participants of the Retroviral Research Center (RRC) longitudinal cohort study of confirmed HIV-infected patients followed for care at the Ramón Ruiz Arnau University Hospital (inpatient and ambulatory clinics) in Bayamón, PR. Invited participants were HIV-infected adults 18 years of age or older followed for HIV care at the RRC and its clinics. After consent was obtained, a baseline questionnaire was administered, and baseline laboratory tests were performed. The baseline questionnaire included 12 months of retrospective medical history supplemented with hospital and medical record abstraction (9). Participants were then interviewed at 6-month intervals thereafter and compensated $10 towards their transportation expenses. The institutional review board of the Universidad Central del Caribe approved the study. More details regarding inclusion criteria for the general cohort study, patient consent, and IRB approval have been published elsewhere (9, 10).

The RRC is the only center that has followed (since 1992) an open cohort of HIV/AIDS patients presenting for care in the Bayamón area (11), and this cohort is the only large HIV cohort on the island. RRC collects information on patient factors via a registry organized into various categories, including socio-demographics; risk-related practices; psychosocial, clinical, and immunological modules; and standard surveillance information (e.g., mode of transmission and CD4 and viral load counts). The Bayamón area is 1 of 8 health care regions in PR (12) and contains 16% of the island population and the second highest HIV/AIDS prevalence (13).

We defined LT (per the CDC definition) as receiving an AIDS diagnosis within 1 year of having one's first reported positive HIV test (14). Given that some of the factors associated with LT might also be associated with delayed entry into HIV care, the study sample was further restricted to include only those late testers, with timely entry defined as joining the study cohort within 1 year of one's first reported positive HIV test. This restriction was done to minimize potential confounding by care delays and to decrease opportunities for LT misclassification (15). The 1-year time span to define timely entry is within the range of other published studies (16). In the cohort study, AIDS was defined per the 1993 CDC AIDS definition (17), which includes immunological (CD4 count<200 cells/mm3) and/or clinical (the presence

of an AIDS-defining condition) diagnoses. HIV and AIDS diagnoses dates were abstracted from medical records. Every cohort participant who had an available date of entry into the study and a first reported HIV test date was included in our analysis.

Demographics, illicit drug use, lifestyle, and clinical characteristics extracted from the modular questionnaires were described by gender and LT status. Mode of transmission included heterosexual, men who have sex with men (MSM), and injection drug use (IDU). Lifestyle covariates and drug use were collected as "ever use" (yes/no), with the exception of a variable asking patients reporting a history of IDU if they had injected such drugs at any time in the year before the study enrollment. Using this information, the following trichotomous variables were created: "non-IDU," "recent IDU" (if the participant had injected drugs in the year prior to study entry), and "remote IDU" (if the participant reported IDU but claimed additionally that such use had not taken place in the year prior to study enrollment).

Pearson's chi-square test was used to compare differences in the distribution of categorical variables by LT. Student's t-test was used to compare means for normally distributed continuous variables by LT status, and the Wilcoxon rank-sum test was used to test the difference between medians for non-normally distributed continuous variables by LT status. Statistically significant associations (2-sided alpha of <0.05) for LT in the bivariate analysis were entered simultaneously into a multivariable logistic regression model. Effect modification by gender and IDU level (recent versus remote) was examined based on observed differences in risk factors for LT among males and IDU in bivariate analysis. Crude odds ratios (OR) or adjusted odds ratios (AOR) and 95% confidence intervals (CI) are reported. Cumulative AIDS prevalence was calculated as the proportion of total AIDS diagnoses among the sample of HIV-infected patients. Changes in LT trends over time were measured with the Cochran-Armitage test and stratified by gender and mode-of-transmission categories. Statistical analysis was conducted using SAS 9.2 (Cary, NC).

Results

RRC cohort patients

From 2000 to 2011, a total of 1582 patients entered the cohort. The median age was 40 years (range 18 to 79 years). Most patients were men (66%, including 29% MSM), nearly one third did not complete the 10th grade of education (31%), and over one third (35%) of all the study participants had been imprisoned at least once. The most common modes of transmission were heterosexual (50%) and IDU (33%, including the MSM/IDU category). Most of the study participants (99%) reported illicit drug use. Cocaine was reported as the most commonly used drug (53%); 26% of the users who reported having taken cocaine further clarified that it had been crack cocaine. Over a third (35%) of the study participants had

injected drugs at some point in their lifetime; most of these last (60%) were recent injectors. The proportion reporting IDU was higher among men (42%) than women (20%) (Table 1).

Overall, 45% (n = 719) of the cohort were diagnosed with AIDS at enrollment. Seventy-eight percent had immunologic AIDS (n = 562), 18% (n = 127) had both clinical and immunologic AIDS, and approximately 2% (n = 17) had clinical AIDS, alone (Figure 1). The median number of days from first reported positive HIV test to entry into the study was 353 (interquartile range [IQR] = 64 – 2615 days). The median CD4 count and HIV viral loads were 253 cells/mm3 (IQR = 80 - 470 cells/mm3), and 38,200 copies/mL (IQR = 2,950 - 204,000 copies/mL), respectively. Thirty-five percent (n = 546) of the study participants had an HIV viral load greater than 100,000 copies/mL. The median CD4 and viral load counts did not differ significantly by gender (p = 0.07 and p = 0.19, respectively).

Analytic sample

Among those who entered the study within 1 year of their first reported positive HIV test (n = 795) (timely entry), the median number of days from the HIV test to entry into the cohort, was 64 (IQR = 43 - 96). The median CD4 count and HIV viral load were 216 cells/mm3 (IQR = 57 - 433 cells/mm3) and 73,670 copies/mL (IQR = 12,200 - 346,750 copies/mL), respectively. These participants were less likely to be male, smokers, or drug users and were less likely to report a history of incarceration. The proportion of patients who reported IDU as their mode of transmission was 19% (compared to 33% of the entire study population that so reported) (Table 1).

Nearly half (47%, n = 377) of those with timely entry already had a recorded AIDS diagnosis and were classified as LT. Ninety percent (n = 339) of late testers had an AIDS diagnosis within the first 3 months after their first reported positive HIV test, including 49% (n = 184) who were concurrently diagnosed with HIV and AIDS at entry (Figure 2). Most AIDS diagnoses were immunological (77%, n = 289) (Figure 1). The median CD4 and viral load counts among the LT group were 54 cells/mm3 (IQR = 21 - 116 cells/mm3) and 253,680 copies/mL (IQR = 73,670 - 684,000 copies/mL), respectively, compared to 420 cells/mm3 (IQR = 295 - 596 cells/mm3) and 23,700 copies/mL (IQR = 4190 - 82120 copies/mL), respectively,

Table 1. Characteristics of HIV-infected patients whose entry into care in the RRC cohort from 2000 to 2011 was timely.

	Overall N = 1582	Timely entry* (n = 795) (%)	Entry not timely (n = 787)	p-Value	OR (95% CI)
Gender (n = 1582)				0.03	0.80 (0.65 to 0.98)
Male	1051 (66%)	508 (64)	543 (69)		
Female	531 (34%)	287 (36)	244 (31)		
Age in years (n = 1582)				0.06	
<30	224 (14)	124 (16)	100 (13)		REF
30–44	845 (53)	402 (50)	443 (56)		0.60 (0.44 to 0.82)
≥45	513 (32)	269 (34)	244 (31)		0.74 (0.53 to 1.03)
Education (n = 1569)				0.28	
≤9th grade	485 (31)	236 (30)	249 (32)		0.84 (0.65 to 1.09)
10-12th grade	612 (39)	299 (38)	313 (40)		0.86 (0.67 to 1.10)
>12th grade	472 (30)	251 (32)	221 (28)		REF
Lifestyle profile (lifetime)					
Smokes (n = 1576)	1134 (72)	522 (66)	612 (78)	<0.01	0.54 (0.43 to 0.68)
Uses alcohol (n = 1575)	811 (51)	417 (53)	394 (50)	0.33	1.1 (0.91 to 1.34)
Has been in prison (n = 1570)	547 (35)	178 (23)	369 (47)	<0.01	0.33 (0.26 to 0.41)
CDC mode of transmission categories (n = 1495)				<0.01	
IDU	447 (30)	139 (18)	308 (42)		0.28 (0.22 to 0.36)
IDU/MSM	38 (2.5)	6 (1)	32 (4)		0.12 (0.05 to 0.29)
MSM	262 (17.5)	151 (20)	111 (15)		0.87 (0.65 to 1.15)
Hetero	748 (50)	458 (61)	290 (39)		REF
Drug use prevalence (ever)					
Cocaine and crack (n = 1578)	833 (53)	323 (41)	510 (65)	<0.01	0.37 (0.30 to 0.45)
Cannabinoid (n = 1575)	729 (46)	305 (38)	424 (54)	<0.01	0.53 (0.43 to 0.64)
Heroin (n = 1577)	590 (37)	200 (25)	390 (50)	<0.01	0.34 (0.28 to 0.42)
Speedball (n = 1572)	517 (33)	166 (21)	351 (45)	<0.01	0.33 (0.26 to 0.41)
Amphetamine (n = 1570)	369 (24)	130 (16)	239 (31)	<0.01	0.45 (0.35 to 0.57)
Ecstasy (n = 1120)	42 (4)	18 (3)	24 (4)	0.32	0.73 (0.39 to 1.36)
IDU (n = 1575)				<0.01	
Remote IDU	200 (13)	56 (7)	144 (18)		0.24 (0.17 to 0.34)
Recent IDU	344 (22)	113 (14)	231 (30)		0.30 (0.23 to 0.39)
Non-IDU	1031 (65)	623 (79)	408 (52)		REF

*Timely entry = entered cohort within 1 year of first reported HIV test

Figure 1. Flow diagram showing the distribution of AIDS diagnoses for patients who entered the cohort within one year of their first reported HIV tests versus that of those entering after one year of their first reported HIV test. *Patients had no or missing data with respect to viral load, CD4 counts, or both; patients had specific dates of first AIDS diagnoses.


Figure 2. Distribution of time to AIDS diagnosis (in months) among 377 late testers (LT).

for non-late testers. Among late testers, the CD4 count was similar for males and females. However, the median viral load was significantly lower in males (209,630; IQR = 67,400 - 594,000) compared to females (404,875 copies/mL; IQR = 97,100 - 750,000) (p = 0.02).

Factors associated with late testing

Factors independently associated with increased odds of LT included being male, being in the older age category, compared to the younger age categories, and reporting IDU (Table 2). Having a history of imprisonment and a history of amphetamine use decreased the odds of LT. Factors remaining significantly associated with LT in the multivariable logistic model were being

male (AOR = 1.59; 95% CI = 1.15 to 2.17), being of a relatively older age (30-44 years: AOR = 1.68; 95% CI = 1.09 to 2.62; ≥45 years: AOR = 3.31; 95% CI = 2.08 to 5.27), remote IDU (AOR = 2.42; 95% CI = 1.24 to 4.69), and having a history of amphetamine use (AOR = 0.52; CI = 0.31 to 0.87).

Trends in late testing over time

Yearly LT prevalence ranged from a high of 58% to a low of 32%. Overall, LT prevalence showed a significantly decreasing yearly trend during the study period (from 47% in 2000 to 36% in 2011, p = 0.04, n = 795; Figure 3a). Among males, only those reporting MSM as their mode of transmission showed a statistically significant decrease in prevalence of LT from 67% in 2000 to 33% in 2011 (p<0.01, n = 151; Figures 3a and b). Also among males, non-statistically significant increasing yearly trend of LT prevalence was observed for heterosexual transmission (46% to 54%; p = 0.72, n = 255; Figure 3c).

Discussion

This is the first study to determine and, subsequently, describe risk factors for LT among HIV-infected patients on the island of Puerto Rico. Being male, being of a relatively older age, and reporting having a remote (past) history of IDU and amphetamine use were all associated with LT in this cohort. Nearly half of the patients studied presented to care late, which is substantially higher than what has been seen in the US (32%), suggesting that LT should be a priority issue for interventions in this population.

Table 2. Characteristics of HIV patients entering "timely" care (as defined in the Analytical Sample section) at the UCC-RCC from 2000 to 2011, by LT status:

	Timely entry* n = 795 (%)	Late (AIDS dx) n = 377 (%)	Not Late (no AIDS dx) n = 418 (%)	p-Value	OR (95% CI)
Gender (n = 795)				0.04	
Male	508 (64)	255 (68)	253 (61)		1.36 (1.02 to 1.82)
Female	287 (36)	122 (32)	165 (39)		REF
Age (n = 795)				<0.01	
<30	124 (16)	40 (11)	84 (20)		REF
30–44	402 (50)	174 (46)	228 (54)		1.7 (1.1 to 2.6)
≥45	269 (34)	163 (43)	106 (25)		3.4 (2.1 to 5.3)
Education (n = 786)				0.16	
≤9th grade	236 (30)	124 (33)	112 (27)		1.4 (0.98 to 1.99)
10–12th grade	299 (38)	136 (37)	163 (39)		1.1 (0.75 to 1.46)
>12th grade	251 (32)	112 (30)	139 (34)		REF
Lifestyle profile (ever)					
Smokes (n = 792)	522 (66)	244 (65)	278 (67)	0.64	0.93 (0.69 to 1.25)
Uses alcohol use (n = 791)	417 (53)	208 (55)	209 (50)	0.14	1.23 (0.93 to 1.63)
Stay in prison (n = 788)	178 (23)	71 (19)	107 (26)	0.02	0.68 (0.48 to 0.95)
CDC mode of transmission categories (n = 795)				0.43	
IDU	139 (18)	61 (17)	78 (20)		0.80 (0.54 to 1.17)
IDU/MSM	6 (1)	2 (0.6)	4 (1)		0.51 (0.09 to 2.81)
MSM	151 (20)	67 (19)	84 (21)		0.81 (0.56 to 1.18)
Hetero	458 (61)	228 (64)	230 (58)		REF
Drug prevalence					
Cocaine and crack (n = 794)	323 (41)	147 (39)	176 (42)	0.36	0.88 (0.66 to 1.16)
Cannabinoid (n = 794)	305 (38)	133 (35)	172 (41)	0.08	0.78 (0.58 to 1.04)
Heroin (n = 793)	200 (25)	86 (23)	114 (27)	0.15	0.79 (0.57 to 1.1)
Speedball (n = 789)	166 (21)	68 (18)	98 (24)	0.06	0.72 (0.51 to 1.02)
Amphetamine (n = 790)	130 (16)	44 (12)	86 (21)	<0.01	0.51 (0.34 to 0.75)
Ecstasy (n = 565)	18 (3)	5 (2)	13 (4)	0.10	0.42 (0.15 to 1.21)
IDU (n = 792)				<0.01	
Remote IDU	56 (7)	34 (9)	22 (5)		1.62 (0.93 to 2.84)
Recent IDU	113 (14)	38 (10)	75 (18)		0.53 (0.34 to 0.81)
Non-IDU	623 (79)	304 (81)	319 (77)		REF

*Timely entry = entered cohort within 1 year of first reported HIV test

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
Overall trend (p = 0.04)	47%	54%	53%	51%	51%	58%	32%	45%	43%	50%	40%	36%
Males (p = 0.04)	49%	52%	64%	52%	60%	64%	33%	45%	42%	54%	37%	42%
Females (p = 0.56)	43%	56%	38%	48%	30%	50%	30%	44%	43%	44%	57%	31%

Figure 3a. Yearly trends of LT overall and by gender

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
Heterosexual (p = 0.76)	46%	53%	52%	51%	48%	55%	40%	56%	44%	57%	52%	54%
IDU (p = 0.24)	39%	58%	47%	45%	55%	57%	31%	38%	20%	33%	50%	0%
MSM (p < 0.01)	67%	67%	64%	53%	55%	63%	18%	33%	43%	43%	21%	33%

Figure 3b. Yearly trends of LT by mode of transmission

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
Heterosexual mode of Transmission_males (p = 0.47)	50%	47%	67%	55%	61%	63%	48%	67%	50%	69%	53%	75%
Heterosexual mode of Transmission_females (p = 0.85)	42%	57%	42%	45%	32%	48%	34%	50%	39%	47%	50%	44%

Figure 3c. Yearly trends of LT for heterosexual mode of transmission by gender

Our finding that men are more likely than women to be late testers is consistent with studies reported in Venezuela, France, England, Italy, and the US (18-24) and is consistent with findings that males tend to have lower utilization rates of health services compared to females (23, 25). In addition, since males do not participate in antenatal care, they may have fewer opportunities for HIV screening than females do (23, 25). Our finding that being of a relatively older age is a risk factor for LT is consistent with studies showing that older patients and their physicians may lack risk awareness, which could lead to the progression of HIV to AIDS prior to recognition of the former (26, 27).

Injection drug users often have decreased access to care, social stigma, and fear of legal repercussions, any or all of which may contribute to an increased likelihood of LT and delayed presentation for HIV care (16, 28-30). Our study is unique

because it contained information individually for former, current or never IDU, taking into account the differential risk of former IDU's compared to former or never IDU. Most studies generally describe IDU as having "ever injected" versus "never injected" (16, 28, 31, 32). In our multivariable analysis, having a history of remote IDU was independently associated with increased odds of LT, compared to those with no history of IDU use. Remote injectors might interact with the healthcare system less often than recent injectors do because recent injectors may suffer from health complications possibly resulting from their actions (33-35). Fewer healthcare interactions could reduce the number of opportunities for testing.

Although the association of amphetamine use with a decreased risk of late testing may seem counterintuitive, one suggested explanation for this finding may be the documented frequency of access to care by amphetamine users (36). Amphetamine users have an increased likelihood of undergoing health complications that would tend to increase their interactions with the health care system; for example, dermatological disorders, depression, and violence are all common among amphetamine users (37-43). Any of these interactions could precipitate an HIV test. In an area of high HIV prevalence and substance abuse such as Bayamón, frequent interactions with health care facilities could provide opportunities for at-risk individuals to receive an HIV test (43, 44). While having a history of incarceration did not remain significant in the multivariable analysis, its association (during the bivariate analysis) with decreased odds of LT may be related to the increased opportunities of prisoners to access HIV education and testing (45).

There was a substantial decline in LT among males over a period of 11 years. This trend was driven primarily by the MSM population. The 2006 implementation of routine opt-out HIV testing (46) may have increased HIV testing rates in males relative to females because many females may have already been tested at antenatal clinics (47, 48).

This study had several limitations. One of which is that these results are from a cohort at a single facility and may not be generalizable to the entire HIV-infected population of the island. However, the distribution of age and mode of transmission in this cohort are similar to those detailed in the island's HIV surveillance data (48). In addition, there may be a misclassification of any given first-reported HIV test if the patient to whom it corresponded had undergone HIV testing before the date identified through the cohort interview and medical record abstraction. A method to further validate these dates was not available to the RRC. This study may also be subject to a prevalence–incidence bias which might have exaggerated the relationship between age and LT.

This study demonstrates the fact that LT is an important public health problem in the study cohort. Further studies are needed to examine the prevalence of LT overall and by region. Such a study might be performed using HIV/AIDS public health surveillance data. Given that factors associated with LT, such as (older) age and IDU, are highly prevalent among HIV-infected Puerto Ricans, interventions to reduce LT will need to address issues relevant to the members of these subpopulations. Qualitative and quantitative assessments to understand underlying reasons for LT within these subgroups are needed. Finally an assessment of the adoption of opt-out HIV screening practices on the island may also be helpful to quantify the issue of missed opportunities. Given the disproportionate representation of Puerto Ricans in the US HIV epidemic, efforts to reduce LT in this population may have a significant impact on the epidemiology of HIV in the US.

Resumen

Objetivo: El diagnóstico tardío del VIH (DT) - definido como el desarrollo de SIDA dentro de un año de recibir el diagnóstico inicial de VIH - está asociado con aumento en la transmisibilidad del VIH, disminución en efectividad del HAART y peores consecuencias en general. Los latinos en los Estados Unidos representan 36% del DT; sin embargo información concerniente al DT en Puerto Rico es escasa. Métodos: Usando regresión logística multivariable, identificamos factores asociados al DT y usando la prueba de Cochran-Armitage, determinamos tendencias del DT en un cohorte de pacientes infectados con VIH en tratamiento en una clínica especializada en VIH en Puerto Rico. Resultados: Del 2000 al 2011, 47% de los pacientes elegibles recibieron un DT, con una media de CD4 y carga viral de 54 células/mm3 y 253,680 copias/mL, respectivamente, versus 420 células/mm3 y 23,000 copias/mL en pacientes sin DT. Usando regresión logística mutuamente ajustada, ser hombre, mayor de edad y reportar uso de drogas inyectables en el pasado, aumentó el cociente de probabilidad. El uso de anfetaminas, disminuyó el cociente de probabilidad. Las tendencias al DT disminuyeron solo en el grupo de riesgo hombres que tienen sexo con hombres, de 67% en el 2000 a 33% en el 2011. Conclusión: Estos resultados sugieren una brecha en el esfuerzo hacia la detección temprana del VIH en Puerto Rico que ha disminuido solo en el grupo de riesgo hombre sexo hombre. Se necesita una evaluación de la implementación de las guías actuales para la prueba de VIH en Puerto Rico.

References

1. CDC. HIV Surveillance Report, 2010. 2012 Mar;22. Available at: http://www.cdc.gov/hiv/pdf/statistics_surveillance_report_vol_22.pdf. Accessed Month 02, 2013

2. Lain MA, Valverde M, Frehill LM. Late entry into HIV/AIDS medical care: the importance of past relationships with medical providers. AIDS Care 2007;19:190-194.

3. Robbins GK, Spritzler JG, Chan ES, et al.; AIDS Clinical Trials Group 384 Team. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009;48:350-361.

4. Smit C, Hallett TB, Lange J, Garnett G, de Wolf F. Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One 2008;3:e1949.

5. Fleishman JA, Yehia BR, Moore RD, Gebo KA; HIV Research Network. The economic burden of late entry into medical care for patients with HIV infection. Med Care 2010;48:1071-1079.

6. Humes K, Jones N, Ramirez R. Overview of Race and Hispanic Origin: 2010. 2010 Census Briefs. Washington DC: US Bureau of the Census; 2010.

7. Pérez CM, Marrero E, Meléndez M, et al. Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infect Dis 2010;10:76.

8. Brown A, Patten E. Hispanics of Puerto Rican Origin in the United States, 2011. Pew Hispanic Center. Available at: http://www.pewhispanic.org/files/2013/06/PuertoRicanFactsheet.pdf. Accessed November 1, 2014.

9. Gómez MA, Velázquez M, Hunter RF. Outline of the Human Retrovirus Registry: profile of a Puerto Rican HIV infected population. Bol Asoc Med P R 1997;89:111-116.

10. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-1805.

11. Báez-Feliciano DV, Quintana R, Gómez MA, et al. Trends in the HIV and AIDS epidemic in a Puerto Rican cohort of patients: 1992-2005. Bol Asoc Med P R 2006;98:174-183.

12. US Bureau of the Census. Statistical Abstract of the United States: 2011. 130th ed. Washington, DC: US Bureau of the Census Bureau; 2011.

13. AIDS Action. State Facts: HIV/AIDS in Puerto Rico. Washington, DC: AIDS Action; 2005:6.

14. Centers for Disease Control and Prevention (CDC). Vital Signs: HIV Testing and Diagnosis Among Adults - United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59:1550-1555. Available at: Url: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5947a3.htm. Accessed March 2, 2013.

15. Schwarcz, SK, Hsu L, Chin CSJ, et al. Do people who develop AIDS within 12 months of HIV diagnosis delay HIV testing? Public Health Rep 2011;126:552-559.

16. Girardi E, Aloisi MS, Arici C, et al. Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 2004;36:951-959.

17. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed March 02, 2013

18. Bonjour MA, Montagne M, Zambrano M, et al. Determinants of late disease-stage presentation at diagnosis of HIV infection in Venezuela: a case-case comparison. AIDS Res Ther 2008;5:6.

19. Couturier E, Schwoebel V, Michon C, et al. Determinants of delayed diagnosis of HIV infection in France, 1993-1995. AIDS 1998;12:795-800.

20. Mugavero MJ, Castellano C, Edelman D, Hicks C. Late diagnosis of HIV infection: the role of age and sex. Am J Med 2007;120:370-373.

21. Chadborn TR, Baster K, Delpech VC, et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005;19:513-520.

22. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002;16:1945-1951.

23. Nacher M, El Guedj M, Vaz T, et al. Risk factors for late HIV diagnosis in French Guiana. AIDS 2005;19:727-729.

24. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006;20:2371-2379.

25. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991;253:37-42.

26. Skiest DJ, Keiser P. Human immunodeficiency virus infection in patients older than 50 years. A survey of primary care physicians' beliefs, practices, and knowledge. Arch Fam Med 1997;6:289-294.

27. Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging 2008;3:453-472.

28. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One 2009; 4:e4445.

29. Adih WK, Campsmith M, Williams CL, Hardnett FP, Hughes D. Epidemiology of HIV among Asians and Pacific Islanders in the United States, 2001-2008. J Int Assoc Physicians AIDS Care (Chic) 2011;10: 150-159.

30. Wand H, Guy R, Law M, Wilson D, Maher L. High Rates of Late HIV Diagnosis Among People Who Inject Drugs Compared to Men Who Have Sex with Men and Heterosexual Men and Women in Australia. AIDS Behav 2013;17:235-241.

31. Wohl AR, Tejero J, Frye DM. Factors associated with late HIV testing for Latinos diagnosed with AIDS in Los Angeles. AIDS Care 2009;21:1203-1210.

32. Ndiaye B, Salleron J, Vincent A, et al. Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007. BMC Infect Dis 2011;11:11.

33. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-661.

34. Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000; 24:162-167.

35. Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health 2001;91:1842-1846.

36. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med 1999;170:198-202.

37. Mooney LJ, Glasner-Edwards S, Rawson RA, Ling W. Medical effects of methamphetamine use. In: Roll JM, Rawson RA, Ling W, Shoptaw S, eds. Methamphetamine Addiction: From Basic Science to Treatment. New York, NY: Guilford Press; 2009:117-142.

38. Darke S, Torok M, Kaye S, Duflou J. Cardiovascular disease risk factors and symptoms among regular psychostimulant users. Drug Alcohol Rev 2010;29:371-377.

39. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med 2007; 120:165-171.

40. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 1998;168:93-97.

41. Darke S, Ross J, Cohen J, Hando J, Hall W. Injecting and sexual risk-taking behaviour among regular amphetamine users. AIDS Care 1995;7:19-26.

42. Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry 1999; 14:366-371.

43. Pilowsky DJ, Wu LT, Burchett B, Blazer DG, Woody GE, Ling W. Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network. Subst Abuse Rehabil 2011;2:133-144.

44. Drug Abuse Warning Network. Emergency department visits involving methamphetamine: 2004-2008. Washington DC: Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services; 2010.

45. Baillargeon JG, Giordano TP, Harzke AJ, Baillargeon G, Rich JD, Paar DP. Enrollment in Outpatient Care Among Newly Released Prison Inmates with HIV Infection. Public Health Rep 2010;125 Suppl 1: 64-71.

46. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1–17.

47. Zetola NM, Grijalva CG, Gertler S, et al. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003-June 2007. PLoS One 2008;3:e2591.

48. Puerto Rico HIV/AIDS Surveillance Summary, Cumulative HIV/AIDS Cases Diagnosed as of June 29, 2012. HIV/AIDS Surveillance Program. Office of Epidemiology and Research, Puerto Rico Health Department. eHARS System. June 29, 2012. Available at: http://www.salud.gov.pr/Programas/OficEpidemiologia/Estadisticas%20Generales/Puerto%20Rico%20HIV%20AIDS%20Surveillance%20Summary%20junio%202012.pdf. Accessed October, 21, 2012.